Midatech Pharma PLC Midatech selects MTR104 for liver cancer treatment
November 15 2016 - 2:01AM
RNS Non-Regulatory
TIDMMTPH
Midatech Pharma PLC
15 November 2016
15 November 2016
Midatech Pharma PLC
("Midatech" or the "Company")
Midatech selects MTR104 candidate for treatment of liver
cancer
Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international
specialty pharmaceutical company focused on developing and
commercialising products in oncology, has today announced that,
following intensive research over the past two years with its gold
nanoparticle technology, it has selected its wholly-owned candidate
compound, MTR104, to take into a formal IND-enabling programme
during 2017, followed by human studies planned for 2018.
The programme is focused on advanced liver cancer where current
chemotherapeutic treatment options are limited and the typical
survival period is six months. Midatech is pursuing improved forms
of cancer therapy based on combining marketed chemotherapeutic
medicines with tumour-targeting molecules or peptides on the same
nanoparticle-based conjugate. The aim is to allow highly toxic
drugs to be specifically targeted to and delivered at the tumour
cells while sparing normal tissue, thereby reducing side effects
and enhancing efficacy.
Commenting on this candidate selection, Jim Phillips, CEO of
Midatech Pharma, remarked: "In-line with the internal development
strategy as announced in conjunction with the Company's recent
fundraise, candidate selection of MTR104 follows a comprehensive
research and development programme that included very encouraging
targeting and tumour reduction data in the preclinical setting, and
we are looking forward to progressing MTR104 through development
into the clinic as we hope to make a difference for patients
suffering from this severe disease."
- Ends -
For more information, please contact:
Midatech Pharma PLC
Jim Phillips, CEO
Tel: +44 (0)1235 888300
www.midatechpharma.com
Panmure Gordon (UK) Limited (Nominated Adviser and Broker)
Corporate Finance
Freddy Crossley / Duncan Monteith
Broking
Tom Salvesen
Tel: +44 (0)20 7886 2500
Consilium Strategic Communications (Financial PR)
Mary-Jane Elliott / Ivar Milligan / Hendrik Thys
Tel: +44 (0)20 3709 5700
Email: midatech@consilium-comms.com
Westwicke Partners (US Investor Relations)
Chris Brinzey
Tel: +1 339 970 2843
Email: chris.brinzey@westwicke.com
Notes for Editors
About Midatech Pharma PLC
Midatech is an international specialty pharmaceutical company
focused on oncology and other therapeutic areas with a US
commercial operation marketing four cancer care supportive
products, and co-promoting two others. Midatech's strategy is to
internally develop oncology products and collaborate with partners
in other therapy areas, and to drive growth both organically and
through strategic acquisitions. The Company's R&D activities
are supported by two breakthrough drug delivery technologies:
Q-Sphera for sustained release and our proprietary gold
nanoparticles. The Group, listed on AIM: MTPH and Nasdaq: MTP,
employs c.[110] staff in four countries. For further company
information see: www.midatechpharma.com
About our gold nanoparticle (GNP) technology
The patented gold nanoparticle (GNP) technology has been
developed to improve key parameters when bound to existing and new
drugs. GNPs comprise of a core of gold metal atoms to which an
organic layer of carbohydrates or glycans (e.g. glucose, galactose
or lactose) are attached via gold-sulphur bonds. Linkers for
therapeutic agents (e.g. small molecules and chemotherapeutics) and
peptides (e.g. insulin) - are attached to the gold core during the
self-formation process. This process involves intricate yet
uncomplicated synthesis that produces multi-component particles
that may deliver multiple drug molecules to the targeted site. The
GNP platform has potential uses in Oncology, Immunology/
Auto-immunology and Neurology, amongst others.
Forward-Looking Statement
Certain statements in this press release may constitute
"forward-looking statements" within the meaning of legislation in
the United Kingdom and/or United States. Such forward-looking
statements include, but are not limited to, statements regarding
the ability of Midatech to successfully test, manufacture, produce
or commercialize products for conditions using the nanoparticle and
sustained release drug delivery platforms, and the ability for
products in development to achieve positive clinical results, and
the ability to meet or achieve timelines associated with
pre-clinical studies, clinical trials or regulatory submissions.
Any forward-looking statements are based on currently available
competitive, financial and economic data together with management's
views and assumptions regarding future events and business
performance as of the time the statements are made and are subject
to risks and uncertainties. We wish to caution you that there are
some known and unknown factors that could cause actual results to
differ materially from any future results, performance or
achievements expressed or implied by such forward-looking
statements.
Reference should be made to those documents that Midatech shall
file from time to time or announcements that may be made by
Midatech in accordance with the London Stock Exchange AIM Rules for
Companies ("AIM Rules"), the Disclosure and Transparency Rules
("DTRs") and the rules and regulations promulgated by the US
Securities and Exchange Commission, which contains and identifies
other important factors that could cause actual results to differ
materially from those contained in any projections or
forward-looking statements. These forward-looking statements speak
only as of the date of this announcement. All subsequent written
and oral forward-looking statements by or concerning Midatech are
expressly qualified in their entirety by the cautionary statements
above. Except as may be required under the AIM Rules or the DTRs or
by relevant law in the United Kingdom or the United States,
Midatech does not undertake any obligation to publicly update or
revise any forward-looking statements because of new information,
future events or otherwise arising.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEAPFLFESKFFF
(END) Dow Jones Newswires
November 15, 2016 02:01 ET (07:01 GMT)
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Apr 2024 to May 2024
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From May 2023 to May 2024